Glaxo forecasts rise in profit as it prepares for spin-off

Company aims to boost the performance of businesses as activist investor pressures CEO Emma Walmsley

Charging cancer drugmaker Roche over pricing could backfire

Multinational company targeted for alleged excessive pricing of the patented breast cancer drug Herceptin

Siemens SA and Aspen join forces to enhance vaccine production for Africa

Aspen is in the process of licensing the rights for the first African Covid-19 vaccines, which it will launch as Aspenovax during the second quarter of 2022

Netcare seeks buyer for underperforming Pretoria hospital

The group says it will be forced to shut Bougainville Hospital if a buyer is not found

Ascendis nets R802m from the sale of most of its assets

The sale of three of its businesses will leave the group with R200m in cash after debt is extinguished

Aspen Pharmacare looking good at the price, say analysts

The pharmaceutical group expects Heps to rise more than a third in its 2022 half year, benefiting from lower finance costs

Ascendis names independent adviser to review its chaotic AGM

Ascendis says an internal recount of its December AGM showed errors, but they wouldn't change the outcome

Ascendis names Harry Smit as chair as CEO quits after three weeks

The healthcare company saw a surprise board shake-up in December and has also struck a new deal with lenders

Philips shares plunge after profit warning and ventilator recall

Dutch health technology company’s supply chain problems add to worries over the recall of up to 5-million ventilators

Biogen tumbles as Medicare limits Alzheimer drug coverage

The decision, taken over efficacy and safety concerns, will hit sales of the controversial drug Aduhelm

Sanofi teams up with AI-driven Exscientia to develop cancer drugs

The deal, part of the French drugmaker’s development plan, could be worth as much as $5.2bn

Ascendis gets new lenders and extra time

A ‘special situations’ Apex investor, along with an SA group, have picked up the struggling firm’s debt and given it two more weeks to solve its problems

Pathology labs agree to slash Covid-19 rapid antigen test prices

PathCare, Lancet and Ampath reach agreement with Competition Commission to cut prices to R150 maximum  per test

Ascendis once again at the brink as lenders call in debt

The group has been given a week to sell assets or find new financiers after a board shake-up

Ascendis board battle: chair ousted and old guard back in

But lenders warn  the unapproved board change allows them to demand immediate repayment of debt

FNB pays out another R5m to a vaccinated customer

SPONSORED | R10m paid out to customers since the start of the competition


Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.